Education

1983 - 1988  Graduate study,   Institute of Virology, Chinese Academy of Preventive Medicine (CAPM), PhD

1978 - 1983  Medical study,  Department of Clinical Medicine, Qingdao Medical College¸ MD

Academic Experience

2007-         Deputy director, State Key Laboratory of Infectious Disease Prevention and Control

2013-2014 Visiting scholar, Scripps Research Institute     

2009.8-10  Distinguished Scientist in Residence, Harvard University

2002-2022 Chief Expert on AIDS, Chinese Center for Disease control and Prevention (China CDC); Director, Division of Research on Virology and Immunology, National Center for AIDS/STD Control and Prevention, China CDC

1998-2001 Deputy Director, National Center for AIDS/STD Control and Prevention (NCAIDS), Chinese Academy of Preventive Medicine; Director, National AIDS Reference Laboratory, NCAIDS

1995-1997 Professor, Director of the AIDS Reference Laboratory, Institute of Virology, Chinese Academy of Preventive Medicine

1993-1995 Visiting Scientist, Institute of Medical Microbiology and Hygiene, Regensburg University, Regensburg, Germany

1990-1995 Associate professor, Vice Director, Department of Tumor Viruses and Department of HIV,   Institute of Virology, Chinese Academy of Preventive Medicine

1989.5-12  Consultant, Biomedical Research Unit, Global Program on AIDS, WHO, Geneva, Switzerland

1988-1989 Vice Director, Department of Tumor Viruses and Department of HIV, Institute of Virology, Chinese Academy of Preventive Medicine

Overview of Academic Research

Dr. Shao’s research areas include HIV molecular epidemiology, HIV drug resistance surveillance, Immunology and vaccine research.

He led a national expert group to set up three national HIV laboratory networks conducting HIV diagnosis, molecular epidemiology and drug resistance surveillance. His team identified the origin and tracked down the geographic spreads of HIV-1 and HIV2 clades and discovered 7 circulating recombinant forms of HIV-1 in China. His work has first shown that the HIV treatment as prevention strategy discovered by NIH clinical trial is working in the real world of public health treatment campaign. His lab was accredited as the WHO Regional Laboratory for HIVDR genotyping to support the HIVDR testing in Asia-Pacific area.

His team conducted the novel HIV vaccine research based on re-designing HIV immunogen, inspired by the first lentivirus vaccine (EIAV vaccine) and replicating vaccinia vector, derived from the Chinese small pox vaccine using priming and boost immune regime. The vaccines are under preparation for Phase II b trials in China by Chinese program and also in collaboration with NIH by boosting with gp140 and gp145 trimer immunogens. When the Covid-19 epidemic struck, his lab dedicated to the universal vaccine research and neutralizing antibody study against Covid-19.

He published 900 research papers in English and Chinese journals and got several China’s national Science and Technology Awards. He got the Distinguishing Young Scholar grant from National Natural Science Foundation of China, Distinguished Scientist in Residence from Harvard, International Research chair grant from IDRC of Canada and Comprehensive International Program for AIDS from NIH.  

Major Honor and Awards

1.  He served as chair and vice chair on the National AIDS Expert Committee, Chinese virology, Microbiology and AIDS Societies. During the Covid-19 epidemic, he served as the member of the vaccine expert group of the Joint Prevention and Control Mechanism of the State Council. Internationally, he is the member of the WHO’s Strategic and Technical Advisory Committee for HIV/AIDS, Vaccine Product Development Vaccine Advisory committee, HIV Vaccine Advisory Committees, HIV Vaccine Advisory Committee, HIVResNet Steering Committee. He was the member of the International Committee on Taxonomy of Viruses, the Scientific Advisory Board of the Grand Challenge in Global Health program of the Bill&Melinda Gates Foundation, as well as consultant to Toward an HIV Cure Initiative of the International AIDS Society.

2.  He is elected the fellow of the American Academy of Microbiology in 2010. and the Gamaleya Medal from Gamaleya National Center for Epidemiology and Microbiology in 2018.

3.  He was awarded National Awards for Advanced Worker by the State Council in 2005, National Award for Outstanding Science Researcher in 2014 and national outstanding individuals in the fight against COVID-19 in the national science and technology system in 2021.

 

 

Representative Research Achievements 

1. Wu D, Ye Y, Tang L, Wang AB, Zhang R, Qian ZH, Wang FZ, Zheng H, Huang C, Lv XY, Wang HF, Zhang YY, Pan JJ, Li YF, Lu MX, Wang CS, Ma YT, An ZJ, Rodewald LE, Yin ZD*, Wang XY*, Wu ZY*, Shao YM*. A case-case study on the effect of primary and booster immunization with China-produced COVID-19 vaccines on prevention of pneumonia and viral load among vaccinated persons infected by Delta and Omicron variants. Emerg Microbes Infect. 2022 Dec;11(1):1950-1958.

2. Qiang Liu, Yue Li, Zhenwu Luo, Guibo Yang, Yong Liu, Ying Liu, Maosheng Sun, Jiejie Dai, Qihan Li, Chuan Qin, Yiming Shao. HIV-1 vaccines based on replication-competent Tiantan vaccinia protected Chinese rhesus macaques from simian HIV infection. AIDS. 2015 Mar 27; 29(6):649-58.  

3. Ge Z, Feng Y, Li K, Lv B, Zaongo SD, Sun J, Liang Y, Liu D, Xing H, Wei M, Ma P, Shao Y*. CRF01_AE and CRF01_AE Cluster 4 Are Associated With Poor Immune Recovery in Chinese Patients Under Combination Antiretroviral Therapy. Clin Infect Dis. 2021 May 18;72(10):1799-1809

4. Liu L, Wang L, Zhang H, Ou W, Li D, Feng Y, Zhuang H*, Shao Y*. Changing Epidemiology of Hepatitis B Virus and Hepatitis C Virus Coinfection in a Human Immunodeficiency Virus-Positive Population in China: Results From the Third and Fourth Nationwide Molecular Epidemiologic Surveys. Clin Infect Dis. 2021 Aug 16;73(4):642-649.

5. Kumar S, Ju B, Shapero B, Lin X, Ren L, Zhang L, Li D, Zhou Z, Feng Y, Sou C, Mann CJ, Hao Y, Sarkar A, Hou J, Nunnally C, Hong K, Wang S, Ge X, Su B, Landais E, Sok D, Zwick MB, He L, Zhu J*, Wilson IA*, Shao Y*. A VH1-69 antibody lineage from an infected Chinese donor potently neutralizes HIV-1 by targeting the V3 glycan supersite. Sci Adv. 2020 Sep 16;6(38):eabb1328.

6. Song H, Ou W, Feng Y, Zhang J, Li F, Hu J, Peng H, Xing H, Ma L, Tan Q, Li D, Wang L, Wu B, Shao Y*. Disparate impact on CD4 T cell count by two distinct HIV-1 phylogenetic clusters from the same clade. Proc Natl Acad Sci U S A. 2019 Jan 2;116(1):239-244.

7. Fan J, Liang H, Ji X, Wang S, Xue J, Li D, Peng H, Qin C, Yee C*, Shao Y*. CTL-mediated immunotherapy can suppress SHIV rebound in ART-free macaques. Nat Commun. 2019 May 21;10(1):2257.

8. Li F, Ma L, Feng Y, Ruan Y, Hu J, Song H, Liu P, Ma J, Rui B, Kerpen K, Scheinfeld B, Srivastava T, Metzger D, Li H4, Bar KJ*, Shao Y*. HIV-1 and hepatitis C virus selection bottleneck in Chinese people who inject drugs. AIDS. 2018 Jan 28;32(3):309-320.

9. Kong L, Ju B, Chen Y, He L, Ren L, Liu J, Hong K, Su B, Wang Z, Ozorowski G, Ji X, Hua Y, Chen Y, Deller MC, Hao Y, Feng Y, Garces F, Wilson R, Dai K, O'Dell S, McKee K, Mascola JR, Ward AB, Wyatt RT, Li Y, Wilson IA, Zhu J*, Shao Y*. Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor. Immunity. 2016 Apr 19;44(4):939-50

10. Jia Z, Mao Y, Zhang F, Ruan Y, Ma Y, Li J, Guo W, Liu E, Dou Z, Zhao Y, Wang L, Li Q, Xie P, Tang H, Han J, Jin X, Xu J, Xiong R, Zhao D, Li P, Wang X, Wang L, Qing Q, Ding Z, Chen RY, Liu Z*, Shao Y*. Antiretroviral therapy to prevent HIV transmission in serodiscordant couples in China (2003-11): a national observational cohort study. Lancet, 2013 Oct 5;382(9899):1195-1203.